Oral Semaglutide Drops

Oral Semaglutide Drops are a compounded sublingual formulation of semaglutide — a GLP-1 (glucagon-like peptide-1) receptor agonist — designed to be absorbed through the mucous membranes under the tongue. As a non-injectable alternative, they offer patients who prefer to avoid needles a pathway to GLP-1 therapy when prescribed by a licensed provider following a thorough online medical visit.

Semaglutide works by binding to GLP-1 receptors in the pancreas, brain, and gastrointestinal tract. This receptor engagement stimulates glucose-dependent insulin secretion, slows gastric emptying, and activates satiety signaling in the hypothalamus. The result is a reduction in perceived hunger and a modulation of food reward pathways, which may help individuals eat less over time when used alongside a reduced-calorie diet and consistent physical activity.

Dosing typically begins at a starter level and is titrated upward over a period of weeks to months, allowing the body to adapt and minimizing the likelihood of gastrointestinal side effects. Your provider will determine the appropriate titration schedule based on your tolerance and clinical response. Adherence to the prescribed protocol and regular follow-up with your care team are important parts of the treatment process.

This formulation may be a fit for adults with a BMI indicating overweight or obesity who are committed to lifestyle modification and are seeking a needle-free GLP-1 option. It is not appropriate for individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). As with all GLP-1 medications, it is prescribed only after a licensed provider reviews your health history through an online consultation.

Common side effects include nausea, vomiting, diarrhea, and constipation, particularly during dose escalation. These effects are often transient and tend to diminish as the body adjusts. Regular provider oversight, including monitoring of relevant health markers, is part of responsible GLP-1 therapy. This is a compounded medication and is not FDA-approved in this format; it is prepared by a licensed 503A compounding pharmacy.